Status:

COMPLETED

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

Lead Sponsor:

Pfizer

Conditions:

Gastrointestinal Stromal Tumors

Eligibility:

All Genders

17+ years

Brief Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...

Detailed Description

All the patients whom an investigator prescribes the first SUNITINIB MALATE(Sutent) should be registered.

Eligibility Criteria

Inclusion

  • Patients need to be administered SUNITINIB MALATE(Sutent) in order to be enrolled in the surveillance.

Exclusion

  • Patients not administered SUNITINIB MALATE(Sutent).

Key Trial Info

Start Date :

April 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2016

Estimated Enrollment :

472 Patients enrolled

Trial Details

Trial ID

NCT00716820

Start Date

April 1 2008

End Date

September 1 2016

Last Update

April 6 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). | DecenTrialz